Breaking the Cycle: Vista's Sacred Journey Recovery Offers Transformative Men's Drug Rehab Amid Rising National Addiction Rates
With national overdose rates remaining high and the U.S. Department of Health and Human Services declaring addiction a public health crisis, treatment centers are adapting to meet complex and changing needs. In many cases, men experience addiction differently than women—facing unique societal pressures that may prevent them from seeking help or expressing emotional vulnerability. Sacred Journey Recovery's gender-specific approach recognizes this disparity and offers a safe, structured space where men can begin to dismantle the behavioral and psychological patterns fueling their substance use.
The men's alcohol rehab program at Sacred Journey Recovery combines a blend of evidence-based clinical therapies, peer support, and experiential healing practices to address addiction from multiple angles. Clients undergo a comprehensive assessment to develop a personalized care plan, which may include Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), group therapy, and individual counseling. These therapeutic interventions aim not only to break physical dependency but also to address unresolved trauma, co-occurring mental health disorders, and emotional regulation challenges.
What distinguishes this Vista-based program is its commitment to holistic healing. Alongside traditional therapeutic models, clients participate in mindfulness practices, physical fitness routines, and Sacred Journey's well-known adventure therapy experiences. These outdoor excursions offer opportunities for real-time learning, stress management, and team-building—giving clients tools they can carry into life beyond treatment. This nature-based approach is especially impactful for men, many of whom benefit from action-oriented recovery methods that reconnect them with a sense of purpose, confidence, and inner strength.
Recent initiatives throughout California underscore the urgency of treatment programs like this one. In 2024, several statewide public health campaigns launched to address rising stimulant and opioid use, particularly among working-age men. Local statistics reveal an alarming increase in polysubstance abuse involving methamphetamine, fentanyl, and benzodiazepines, leading to a spike in emergency room visits and overdose deaths. Communities such as Vista are not exempt from these trends, making local access to high-quality rehab options essential.
Sacred Journey Recovery's alcohol addiction treatment program also addresses the intersection of addiction and mental health, a crucial element of long-term recovery. Many men entering treatment have untreated depression, anxiety, PTSD, or other mental health disorders that fuel their substance use. The center's dual-diagnosis approach ensures that these underlying issues are addressed concurrently with addiction, increasing the likelihood of sustained recovery and a more fulfilling life.
Moreover, the rehab experience is structured around a continuum of care model. After completing residential or intensive outpatient programming, clients have access to aftercare support, sober living referrals, vocational development opportunities, and alumni networks. This wraparound model is designed to reduce relapse risk and empower individuals to reintegrate into their families, communities, and careers with confidence.
At a time when drug addiction continues to fracture families and overwhelm health systems, programs like Sacred Journey Recovery's men's drug rehab offer a path forward rooted in empathy, expertise, and real-world support. The program doesn't just aim to help men stop using drugs—it strives to help them rediscover who they are without them. Through therapeutic exploration, physical activity, emotional connection, and a strong community, clients are given the chance to rebuild their lives from the inside out.
For men in Vista and throughout Southern California seeking meaningful, lasting change, Sacred Journey Recovery's approach provides a beacon of hope amid the noise of crisis—a reminder that recovery is not just possible, but deeply transformational.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
UK government targets manufacturing as it eyes £41bn life science sector growth
The UK Government will enhance manufacturing and commercialisation as it looks to harness the value of the life sciences sector for the country's economy. In a new Life Sciences sector plan, the government outlined a six-point action plan to ensure the sector reaches its forecasted value increase of £41bn, representing a growth of 165% by 2035. The government is aiming to make the UK the leading life sciences economy in Europe, and third largest in the world behind only America and China. While excelling at research and development (R&D), the report outlines difficulties with commercialisation and adoption. For example, despite being the first country to approve a CRISPR-based medicine, Vertex and CRISPR Therapeutics' Casgevy for sickle cell anaemia is primarily commercialised overseas. In a bid to scale industry, the government has pledged £520m to improve life science manufacturing. Outlaid via the Life Sciences Innovative Manufacturing Fund (LSMIF), the investment will aim to expand the UK's manufacturing capabilities and supply chain security. The initiative comes at a crucial time, as British pharmaceutical companies are significantly increasing their investments in the United States. GSK invested $800m in drug substance and drug product manufacturing facilities in the US in October 2024. AstraZeneca – which has a market cap of £162bn – is reportedly plotting a move of its public listing to the US stock exchange in what would be a major blow to the UK economy. To facilitate the industry's expansion, the government will look to increase access to scale-up capital. There has been a cautious domestic investor base, leading to a lull in emerging companies with high economic outputs. The government will measure investment by the number of UK life science companies with a valuation of over £10bn, the number of companies on the FTSE 300, and the number of initial public offerings (IPOs) in the sector. From a regulatory standpoint, the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute of Care and Excellence (NICE) will be supported to provide faster approvals and more efficient reimbursement. Optimism and criticism for UK life sciences MHRA's chief executive Lawrence Tallon welcomed the news, saying: 'It's great to see the MHRA is recognised as a pivotal partner in delivering the plan's vision - by supporting innovation, protecting public health, and making the UK a global destination for innovators to research, develop and launch cutting-edge medical products.' David Stockdale, chief executive of the British Healthcare Trades Association (BHTA) highlighted the importance of reducing regulatory and financial barriers to accelerate faster delivery of innovative MedTech solutions to patients. "We welcome today's announcement which rightly aims to make the UK a leading hub for investment and innovation in lifesaving MedTech, an essential step if we are to improve patient care and cut down waiting times. We particularly welcome the renewed commitments to the Life Sciences Innovative Manufacturing Fund and the NHS Innovator Passports. Our members are eager to deliver their innovative products and services to patients more quickly and efficiently, and we look forward to working with the Government to make this a reality. Clinical trials are set to benefit from the plan, with a new 150 day or lower target for trial set up times. Finally, up to £600m will be put towards an artificial intelligence (AI)-ready health data platform, a strategy already launched in April 2025. The BioIndustry Association (BIA) said: 'The life science sector plan is right to focus on getting substantially more public and private investment in early-stage companies, improved access to data, trials and skills to help companies grow, and more streamlined regulation and market access pathways to get innovative medicines to NHS patients.' However, the Association of the British Pharmaceutical Industry (ABPI) commented that the plan falls short of investing in innovative medicines. Richard Torbett, Chief Executive of the ABPI, said: [The UK life sciences sector] has been struggling to remain competitive and attractive to investment. The solutions proposed are necessary and important, but they are not enough to turn around the UK's decline. 'The UK must address the core issue holding back the life sciences sector, the long-term disinvestment in innovative medicines that is increasingly preventing NHS patients from accessing medications that are available in other countries.' The life science sector plan comes hot on the heels of the 10-year health plan unveiled for the NHS earlier this month, which placed emphasis on technology and digitalisation. "UK government targets manufacturing as it eyes £41bn life science sector growth" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
New York Post
4 hours ago
- New York Post
You're brushing your teeth wrong — a common myth you grew up hearing can leave you ‘long in the tooth'
It's time to brush up on your oral hygiene. For decades, Americans have been scrubbing their smiles with the wrong tools and techniques thanks to a deeply ingrained myth. This rough-around-the-edges technique is doing more harm than good, according to Chicago-based dentist Dr. Joy Poskozim. 3 Your rough-around-the-edges technique is doing more harm than good, according to Chicago-based dentist Dr. Joy Poskozim. S Fanti/ – The idea that harder bristles work better to clean your teeth has persisted for ages — but it's not actually true. Hard-bristled brushes can actually wear down enamel over time — a condition called toothbrush abrasion — causing teeth to appear browner, thinner and more brittle, especially around the gumline. Even worse, overly aggressive brushing can irritate the gums to the point that they begin to pull back from the teeth — which is where the phrase 'long in the tooth' comes from, according to Poskozim. 'Starting in the 1950s, softer nylon toothbrush bristles were being created by toothbrush makers like Colgate,' she told The Post. '[But] there are some people to this day that prefer a medium-hardness toothbrush to the soft-bristled brushes.' If you really want bristles that feel a bit firmer, Poskozim recommends an electric toothbrush like the one by Sonicare. 3 'Starting in the 1950s, softer nylon toothbrush bristles were being created by toothbrush makers like Colgate,' Poskozim told The Post. Syda Productions – 'The bristles are soft and the toothbrush is timed for two minutes — so they are brushing longer and, even though the bristles are soft, it feels like a 'harder' brush,' she said. Poskozim notes that the average American only brushes for 37 seconds, which is well below the professional recommendation of a full two minutes. The dentist, who works extensively with older adults, says many patients grew up with dangerous dental beliefs and habits that still linger. Those include: Thinking harder toothbrushes are better Not knowing anything about flossing Never seeing the dentist on a regular basis unless in pain Not having to see a dentist when having baby teeth Having all teeth removed preventatively to prevent toothaches Getting full dentures when you're only 16, 'sometimes still done in the deep South' 3 Overly aggressive brushing can irritate the gums to the point that they begin to pull back from the teeth — which is where the phrase 'long in the tooth' comes from, according to Poskozim. Rasulov – Bristle firmness isn't the only thing that's changed since the '50s — in fact, there have been shifts in dental care since even the late '90s. 'When I graduated from NYU College of Dentistry in 1999, the only thing we knew about the fluoride ion was that it bonded with the surface calcium, helping to prevent bacteria from penetrating into the teeth,' she said. That's because tooth enamel is porous — which is why we feel sensitivity and get stains. But modern science shows fluoride is doing more than just shielding the surface. 'Now we know that fluoride also prevents micronutrients from leaving out teeth, so fluoride keeps teeth 'mineralized,'' she said. Some other old-school myths, according to Poskozim, is that brushing once a day is enough and it's best to brush before breakfast. 'The whole purpose of brushing teeth is to disrupt the oral bacteria from creating cavities from the foods we eat and plaque depositing,' she said. 'Therefore, it is better to brush after meals, not allowing excess food particles to fester in and around our teeth.'
Chicago Tribune
5 hours ago
- Chicago Tribune
Robert F. Kennedy Jr. and other Trump officials embrace psychedelics after FDA setback
WASHINGTON — For decades, proponents of psychedelic drugs have come to Washington with a provocative message: Illegal, mind-altering substances like LSD and ecstasy should be approved for Americans grappling with depression, trauma and other hard-to-treat conditions. A presidential administration finally seems to agree. 'This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months,' Health Secretary Robert F. Kennedy Jr. recently told members of Congress. His suggested timeline for green-lighting psychedelic therapy surprised even the most bullish supporters of the drugs. And it comes as psychedelics are making inroads in deep red states like Texas, where former Trump cabinet secretary and ex-governor Rick Perry has thrown his full support behind the effort. The administration's embrace of psychedelics has sparked both excitement as well as concern from those in the field, who worry the drugs might be discredited if they appear to be rushed onto the market or are too closely linked with Kennedy, who is known for controversial views on vaccines, antidepressants and fluoride. 'I'm quite optimistic,' says Rick Doblin, whose organization has pursued the medical use of MDMA (or ecstasy) since the 1980s. 'But I'm also worried that the message the public might get is 'Well, RFK likes psychedelics and now it's approved.'' Under President Joe Biden, the FDA rejected MDMA as a treatment for post-traumatic stress disorder, citing flawed data and questionable research. Regulators called for a new study, likely taking several years. It was a major setback for Doblin and other advocates hoping to see the first U.S. approval of a psychedelic for medical use. But the agency appears ready to reconsider. FDA chief Marty Makary, who reports to Kennedy, has called the evaluation of MDMA and other psychedelics 'a top priority,' announcing a slate of initiatives that could be used to accelerate their approval. One new program promises to expedite drugs that serve 'the health interests of Americans,' by slashing their review time from six months or more to as little as one month. Makary has also suggested greater flexibility on requirements for certain drugs, potentially waiving rigorous controlled studies that compare patients to a placebo group. That approach, considered essential for high-quality research, has long been a stumbling point for psychedelic studies, in which patients can almost always correctly guess whether they've received the drug or a dummy pill. The U.S. Department of Health and Human Services and FDA also recently hired several new staffers with ties to the psychedelic movement. 'These are all very promising signs that the administration is aware of the potential of psychedelics and is trying to make overtures that they're ready to approve them,' said Greg Ferenstein, a fellow at the libertarian Reason Foundation, who also consults for psychedelic companies. 'We didn't hear anything about that in the Biden administration' A spokesperson for HHS did not respond to a request for comment. As a presidential candidate, Kennedy discussed how his son and several close friends benefited from using psychedelics to deal with grief and other issues. A number of veterans lobbying for psychedelic access have already met with Trump's Secretary of Veterans Affairs, Doug Collins. 'What we're seeing so far is positive,' Collins told House lawmakers in May. But some experts worry the hope and hype surrounding psychedelics has gotten ahead of the science. Philip Corlett, a psychiatric researcher at Yale University, says bypassing rigorous clinical trials could set back the field and jeopardize patients. 'If RFK and the new administration are serious about this work, there are things they could do to shepherd it into reality by meeting the benchmarks of medical science,' Corlett said. 'I just don't think that's going to happen.' As officials in Washington weigh the future of psychedelics, some states are moving ahead with their own projects in hopes of nudging the federal government. Oregon and Colorado have legalized psychedelic therapy. And last month, Texas approved $50 million to study ibogaine, a potent psychedelic made from a shrub that's native to West Africa, as a treatment for opioid addiction, PTSD and other conditions. The research grant — the largest of its kind by any government — passed with support from the state's former GOP governor, Perry, and combat veterans, some who have traveled to clinics in Mexico that offer ibogaine. Ibogaine is on the U.S. government's ultra-restrictive list of illegal, Schedule 1 drugs, which also includes heroin. So advocates in Texas are hoping to build a national movement to ease restrictions on researching its use. 'Governmental systems move slowly and inefficiently,' said Bryan Hubbard of Americans for Ibogaine, a group formed with Perry. 'Sometimes you find yourself constrained in terms of the progress you can make from within.' Ibogaine is unique among psychedelics in both its purported benefits and risks. Small studies and anecdotal reports suggest the drug may be able to dramatically ease addiction and trauma. It was sold for medical use in France for several decades starting in the 1930s, but the drug can also cause dangerous irregular heart rhythms, which can be fatal if left untreated. Some veterans who have taken the drug say the risks can be managed and ibogaine's healing properties go far beyond antidepressants, mood stabilizers, counseling and other standard treatments. Marcus Capone struggled with anger, insomnia and mood swings after 13 years as a Navy Seal. In 2017, at the urging of his wife Amber, he agreed to try ibogaine as a last resort. He described his first ibogaine session as 'a complete purge of everything.' 'But afterward I felt the weight just completely off my shoulders,' he said. 'No more anxiety, no more depression, life made sense all of a sudden.' A nonprofit founded by the Capones, Veterans Exploring Treatment Solutions, or VETS, has helped over 1,000 veterans travel abroad to receive ibogaine and other psychedelics. But federal scientists have looked at the drug before — three decades ago, when the National Institute on Drug Abuse funded preliminary studies on using it as an addiction treatment. The research was discontinued after it identified 'cardiovascular toxicity.' 'It would be dead in the water,' in terms of winning FDA approval, longtime NIDA director Nora Volkow said. But Volkow said her agency remains interested in psychedelics, including ibogaine, and is funding an American drugmaker that's working to develop a safer, synthetic version of the drug. 'I am very intrigued by their pharmacological properties and how they are influencing the brain,' Volkow said. 'But you also have to be very mindful not to fall into the hype and to be objective and rigorous in evaluating them.'
